PMID- 34536264
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20220406
IS  - 1932-8494 (Electronic)
IS  - 1932-8486 (Linking)
VI  - 304
IP  - 11
DP  - 2021 Nov
TI  - Network pharmacology-based investigation to explore the effect and mechanism of 
      Erchen decoction against the nonalcoholic fatty liver disease.
PG  - 2605-2619
LID - 10.1002/ar.24770 [doi]
AB  - This study aimed to uncover the potential mechanism of Erchen decoction (ECD) on 
      the amelioration of nonalcoholic fatty liver disease (NAFLD). Network 
      pharmacology and bioinformatics were used to determine the active components of 
      ECD and its potential target in treating NAFLD. High fat diet (HFD)-induced NAFLD 
      mice model was used. Liver tissues were stained with hematoxylin and eosin, and 
      Oil Red O. Serum lipid profiles and hepatic inflammatory molecules in 
      lipopolysaccharide (LPS)/Toll-like receptor-4 (TLR-4) pathway were confirmed by 
      enzyme-linked immunosorbent assay. Intestinal barrier function, including 
      intestinal epithelial tight junction (IETJ) proteins, fecal short-chain fatty 
      acids (SCFAs) concentration and intestinal microbiota composition, was also 
      assessed. Screening relevant databases revealed 123 active components and 158 
      potential target proteins in ECD, as well as 1,783 differential genes for NAFLD. 
      Enrichment analyses predicted that the regulation of LPS, cholesterol metabolism 
      and inflammatory pathways might be the underlying mechanisms of ECD in NAFLD 
      treatment. ECD ameliorated the multi-profiles of NAFLD and reversed the high 
      levels of inflammatory molecules such as, serum LPS, hepatic TLR-4, tumor 
      necrosis factor-alpha, and interleukin-1beta. Additionally, ECD upregulated the 
      concentration levels of IETJ proteins and fecal SCFAs. 16s RNA sequencing 
      indicated that ECD can improve the gut microbiota, such as Akkermansia, 
      Clostridium XIVa, Coprococcus, and Ruminococcus. The current study demonstrated 
      that ECD can reverse the HFD-induced intestinal barrier dysfunction, thereby 
      reducing the LPS translocation and alleviating the hepatic inflammation, and 
      eventually exhibiting a protective effect against NAFLD.
CI  - (c) 2021 American Association for Anatomy.
FAU - Liu, Haiyan
AU  - Liu H
AUID- ORCID: 0000-0001-9955-1758
AD  - Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Hangzhou, 
      China.
AD  - Digestive Disease Institute of Integrated Traditional Chinese and Western 
      Medicine, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China.
FAU - Xu, Jie
AU  - Xu J
AD  - Graduate School, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Li, Hui
AU  - Li H
AD  - Graduate School, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Zhang, Lina
AU  - Zhang L
AD  - Basic Medical College, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Xu, Pingzhen
AU  - Xu P
AUID- ORCID: 0000-0001-5506-4640
AD  - Endoscopy Center, Tongde Hospital of Zhejiang Province, Hangzhou, China.
LA  - eng
GR  - 82004333/National Natural Science Foundation of China/
GR  - 2016ZX09101069/National science and technology major special projects for the 
      major new drug innovation/
GR  - 2017-XK-B02/The 13th Five-Year Plan of Zhejiang Provincial Key Discipline 
      Construction of Traditional Chinese Medicine/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210918
PL  - United States
TA  - Anat Rec (Hoboken)
JT  - Anatomical record (Hoboken, N.J. : 2007)
JID - 101292775
SB  - IM
MH  - Animals
MH  - Diet, High-Fat/adverse effects
MH  - *Gastrointestinal Microbiome
MH  - Liver/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Network Pharmacology
MH  - *Non-alcoholic Fatty Liver Disease/drug therapy
OTO - NOTNLM
OT  - Erchen decoction
OT  - intestinal barrier function
OT  - network pharmacology
OT  - nonalcoholic fatty liver disease
OT  - traditional Chinese medicine
EDAT- 2021/09/19 06:00
MHDA- 2022/04/07 06:00
CRDT- 2021/09/18 12:13
PHST- 2021/07/17 00:00 [revised]
PHST- 2021/03/31 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/09/19 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2021/09/18 12:13 [entrez]
AID - 10.1002/ar.24770 [doi]
PST - ppublish
SO  - Anat Rec (Hoboken). 2021 Nov;304(11):2605-2619. doi: 10.1002/ar.24770. Epub 2021 
      Sep 18.